

**PROHIBITION OF SALES TO EEA AND UK RETAIL INVESTORS:** The Securities are not intended to be offered, sold or otherwise made available to and may not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("**EEA**") or in the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU on Markets in Financial Instruments (as may be amended) ("**MiFID II**"); (ii) a customer within the meaning of Directive 2016/97/EU (the "**Insurance Distribution Directive**"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (the "**Prospectus Regulation**"). Consequently no key information document required by Regulation (EU) No 1286/2014 (the "**PRIIPs Regulation**") for offering or selling the Securities or otherwise making them available to retail investors in the EEA or in the United Kingdom has been prepared and therefore offering or selling such Securities or otherwise making them available to any retail investors in the EEA or in the United Kingdom may be unlawful under the PRIIPs Regulation.

Following the Brexit implementation period completion day, references in the Base Prospectus (as completed by these Final Terms) to EU legislation will be deemed, for UK purposes, to include references to the corresponding provisions of UK onshored or retained legislation that form part of UK law by virtue of the European Union (Withdrawal) Act 2018 (the "**EUWA**").



**Final Terms dated 11 March 2021**

**Credit Suisse AG, London Branch**

**Legal Entity Identifier (LEI): ANGGYXNX0JLX3X63JN86**

**USD 1,200,000 Trigger Return Equity-linked Securities due March 2024**

linked to a Share Basket (the "**Securities**")

Series SPLB2021-1T8G

ISIN: XS2296366698

issued pursuant to the Trigger Redeemable and Phoenix Securities Base Prospectus

as part of the **Structured Products Programme for the issuance of Notes, Certificates and Warrants**

## **PART A – CONTRACTUAL TERMS**

Terms used herein shall be deemed to be defined as such in the General Conditions, the Product Conditions and the applicable Asset Terms (as may be amended and/or supplemented up to, and including, the Issue Date) set forth in the Securities Note dated 10 July 2020 as supplemented on 23 December 2020 and by any supplements up to, and including, the Issue Date (the "**Securities Note**") which, together with the Registration Document dated 7 April 2020, as supplemented on 17 April 2020, 8 May 2020, 5 August 2020, 15 October 2020, 4 November 2020 7 December 2020, 22 December 2020, 18 January 2021 and 26 February 2021 and by any further supplements up to, and including, the later of the Issue Date and the date of listing of the Securities (together, the "**Registration Document**"), constitutes a base prospectus for the purposes of the Prospectus Regulation (the "**Base Prospectus**"). This document constitutes the Final Terms of the Securities described herein for the purposes of Article 8(4) of the Prospectus Regulation and must be read in conjunction with such Base Prospectus in order to obtain all the relevant information. A summary of the Securities is annexed to these Final Terms. Copies of the documents comprising the Base Prospectus may be obtained from the website of Credit

Suisse (<https://derivative.credit-suisse.com>).

These Final Terms comprise the final terms for the issue and admission to trading on the regulated market of the Luxembourg Stock Exchange of the Securities. The Final Terms will be available on the website of Credit Suisse (<https://derivative.credit-suisse.com>) and for viewing on the website of the Luxembourg Stock Exchange ([www.bourse.lu](http://www.bourse.lu)).

1. Series Number: SPLB2021-1T8G
2. Tranche Number: Not Applicable
3. Applicable General Terms and Conditions: General Note Conditions
4. Type of Security: Trigger Return Securities
5. Settlement Currency: United States Dollar ("**USD**")
6. Institutional: Applicable

**PROVISIONS RELATING TO NOTES AND CERTIFICATES** Applicable

7. Aggregate Nominal Amount:
  - (i) Series: USD 1,200,000
  - (ii) Tranche: Not Applicable
8. Issue Price: 100 per cent. of the Aggregate Nominal Amount
9. Specified Denomination: USD 1,000
10. Minimum Transferable Number of Securities: Not Applicable
11. Transferable Number of Securities: Not Applicable
12. Minimum Trading Lot: Not Applicable
13. Issue Date: 12 March 2021
14. Maturity Date: 5 Currency Business Days following the Final Fixing Date or, if such date falls on different dates for different Underlying Assets, the latest of such dates to occur (expected to be 4 March 2024)
15. Coupon Basis: Applicable: Other Coupon Provisions
16. Redemption/Payment Basis: Equity-linked
17. Put/Call Options: Not Applicable

**PROVISIONS RELATING TO WARRANTS** Not Applicable

*(Paragraphs 18 to 28 have been intentionally deleted)*

**PROVISIONS RELATING TO COUPON AMOUNTS**

29. Fixed Rate Provisions (General Note Condition 4 or General Certificate Condition 4): Not Applicable

30.	Floating Rate Provisions (General Note Condition 4 or General Certificate Condition 4):	Not Applicable
31.	Premium Provisions (General Note Condition 4 or General Certificate Condition 4):	Not Applicable
32.	Other Coupon Provisions (Product Condition 2):	Applicable
	(i) Coupon Payment Event:	Applicable
	(a) Coupon Amount:	If a Coupon Payment Event has occurred:  Memory Coupon  If no Coupon Payment Event has occurred: zero
	(b) Coupon Payment Event:	On the relevant Coupon Observation Date, the Level (with regard to the Valuation Time) of each Underlying Asset is at or above the Coupon Threshold of such Underlying Asset corresponding to such Coupon Observation Date
	(c) Coupon Call/Coupon Put:	Not Applicable
	(d) Memory Coupon:	Applicable
	– Coupon Rate:	2.05 per cent.
	– t:	In respect of a Coupon Payment Date, the number of Coupon Observation Dates falling in the period commencing on, but excluding, the Issue Date and ending on, and including, such Coupon Payment Date
	(ii) Double No-Touch:	Not Applicable
	(iii) Double No-Touch Accrual:	Not Applicable
	(iv) Double No-Touch Memory:	Not Applicable
	(v) Range Accrual:	Not Applicable
	(vi) Step-Up:	Not Applicable
	(vii) Snowball:	Not Applicable
	(viii) Aggregate Coupon:	Not Applicable
	(ix) Aggregate Memory Coupon:	Not Applicable
	(x) Coupon Cap:	Not Applicable
	(xi) Coupon Floor:	Not Applicable
	(xii) FX Adjusted:	Not Applicable
	(xiii) Coupon Payment Date(s):	In respect of a Coupon Observation Date, 5 Currency Business Days following such Coupon Observation Date (or, if such date falls on different dates for different Underlying Assets, the latest of such dates to

	occur)
(xiv) Coupon Threshold:	In respect of a Coupon Observation Date and an Underlying Asset, an amount equal to 70 per cent. of the Strike Price of such Underlying Asset
(xv) Coupon Threshold (Basket):	Not Applicable
(xvi) Coupon Observation Date(s):	In respect of an Underlying Asset, each of 26 May 2021, 26 August 2021, 26 November 2021, 26 May 2022, 26 August 2022, 26 November 2022, 26 February 2023, 26 May 2023, 26 August 2023, 26 November 2023 and 26 February 2024
(xvii) Coupon Observation Date subject to Valuation Date adjustment:	Valuation Date adjustment applicable in respect of all Coupon Observation Dates
(xviii) Coupon Observation Period(s):	Not Applicable
(xix) Coupon Fixing Price:	Not Applicable
(xx) Coupon Fixing Price Cap:	Not Applicable
(xxi) Coupon Fixing Price Floor:	Not Applicable
(xxii) Coupon Observation Averaging Dates:	Not Applicable
(xxiii) Knock-in Coupon Cut-Off:	Not Applicable
(xxiv) Lock-in Coupon:	Not Applicable

#### **PROVISIONS RELATING TO REDEMPTION/SETTLEMENT**

33.	Redemption Amount or (in the case of Warrants) Settlement Amount (Product Condition 3):	Worst of Trigger Redeemable (Star)
(i)	Redemption Option Percentage:	Not Applicable
(ii)	Redemption Performance:	Not Applicable
(iii)	Redemption Amount Cap/Floor:	Not Applicable
(iv)	Redemption Strike Price:	In respect of an Underlying Asset, an amount equal to 65 per cent. of the Strike Price of such Underlying Asset
(v)	Redemption FX Adjustment:	Not Applicable
(vi)	PPT:	Not Applicable
(vii)	Strike:	Not Applicable
(viii)	Nth (for the purposes of determining the Worst Performing Underlying Asset):	1st lowest (i.e. the lowest) as specified in Product Condition 1
34.	Initial Setting Date:	26 February 2021

35. Initial Averaging Dates: Not Applicable
36. Final Fixing Date: 26 February 2024
37. Averaging Dates: Not Applicable
38. Final Price: In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Final Fixing Date
- (i) Final Price Cap: Not Applicable
- (ii) Final Price Floor: Not Applicable
39. Strike Price: In respect of an Underlying Asset, the Level (with regard to the Valuation Time) of such Underlying Asset on the Initial Setting Date
- (i) Strike Cap: Not Applicable
- (ii) Strike Floor: Not Applicable
40. Knock-in Provisions: Not Applicable
41. Knock-out Provisions: Not Applicable
42. Trigger Redemption (Product Condition 3(c)): Applicable
- (i) Trigger Event: On any Trigger Barrier Observation Date, the Level (with regard to the Valuation Time) of each Underlying Asset is at or above the Trigger Barrier of such Underlying Asset
- (ii) Trigger Barrier Redemption Date(s): In respect of a Trigger Barrier Observation Date, as specified in the table below in respect of such Trigger Barrier Observation Date
- (iii) Trigger Barrier Redemption Amount: In respect of a Trigger Barrier Redemption Date, as specified in the table below in respect of such Trigger Barrier Redemption Date
- (iv) Trigger Barrier: In respect of a Trigger Barrier Observation Date and an Underlying Asset, as specified in the table below in respect of such Trigger Barrier Observation Date
- (v) Trigger Barrier Observation Date(s): In respect of an Underlying Asset and a Trigger Barrier Redemption Date, as specified in the table below in respect of such Trigger Barrier Redemption Date
- (vi) Trigger Barrier Observation Date subject to Valuation Date adjustment: Valuation Date adjustment applicable in respect of all Trigger Barrier Observation Dates
- (vii) Trigger Barrier Observation Period(s): Not Applicable

	<b>Trigger Observation Date<sub>n</sub></b>	<b>Barrier Trigger Barrier<sub>n</sub></b>	<b>Trigger Redemption Amount<sub>n</sub></b>	<b>Barrier Trigger Redemption Date<sub>n</sub></b>	<b>Barrier</b>
1.	26 February 2022	An amount equal to 91 per cent. of	An amount equal to 110 per cent. of	5 Business Days	Currency

		the Strike Price of such Underlying Asset	the Nominal Amount	following the occurrence of a Trigger Event
2.	26 May 2022	An amount equal to 88 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
3.	26 August 2022	An amount equal to 85 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
4.	26 November 2022	An amount equal to 82 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
5.	26 February 2023	An amount equal to 79 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
6.	26 May 2023	An amount equal to 76 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
7.	26 August 2023	An amount equal to 73 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
8.	26 November 2023	An amount equal to 70 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
9.	26 February 2024	An amount equal to 70 per cent. of the Strike Price of such Underlying Asset	An amount equal to 110 per cent. of the Nominal Amount	5 Currency Business Days following the occurrence of a Trigger Event
(viii)	Knock-in Event Condition:	Event	Override	Not Applicable
(ix)	Trigger Barrier Fixing Price:			Not Applicable
(x)	Trigger Coupon Condition:	Coupon	Override	Not Applicable
(xi)	Trigger Knock-out Barrier:			Not Applicable

	(xii)	Trigger Knock-out Event:	Not Applicable
	(xiii)	Trigger Knock-out Observation Period Start Date(s):	Not Applicable
	(xiv)	Trigger Knock-out Observation Period End Date(s):	Not Applicable
43.		Lock-in Redemption:	Not Applicable
44.		Single Factor Trigger Redeemable (Step-Up) / Single Factor Trigger Redeemable (Star) / Worst of Trigger Redeemable (Step-Up) / Worst of Trigger Redeemable (Star):	Applicable – Worst of Trigger Redeemable (Star)
	(i)	Level:	For the purposes of Product Conditions 3(a)(ii)(G)(1) and 3(a)(ii)(G)(3): The Level of any Underlying Asset (with regard to the Valuation Time)  For the purposes of Product Condition 3(a)(ii)(G)(2): The Level of each Underlying Asset (with regard to the Valuation Time)
	(ii)	Knock-in Barrier 1:	In respect of an Underlying Asset, an amount equal to 140 per cent. of the Strike Price of such Underlying Asset
	(iii)	Knock-in Rate 1:	100 per cent.
	(iv)	Knock-in Barrier 2:	In respect of an Underlying Asset, an amount equal to 65 per cent. of the Strike Price of such Underlying Asset
	(v)	Knock-in Rate 2:	100 per cent.
	(vi)	Redemption at Nominal Amount:	Not Applicable
	(vii)	Redemption Performance:	Applicable
	(viii)	Knock-in Observation Date:	In respect of an Underlying Asset, 26 February 2024
	(ix)	Knock-in Observation Date subject to Valuation Date adjustment:	Valuation Date adjustment applicable in respect of the Knock-in Observation Date
45.		Details relating to Instalment Securities:	Not Applicable
46.		Physical Settlement Provisions (Product Condition 4):	Not Applicable
47.		Put Option:	Not Applicable
48.		Call Option:	Not Applicable
49.		Unscheduled Termination Amount:	

- (i) Unscheduled Termination at Par: Not Applicable
  - (ii) Minimum Payment Amount: Not Applicable
  - (iii) Deduction for Hedge Costs: Not Applicable
50. Payment Disruption: Not Applicable
51. Interest and Currency Rate Additional Disruption Event: Not Applicable

**UNDERLYING ASSET(S)**

52. List of Underlying Asset(s): Applicable

i	Underlying Asset <sub>i</sub>	Weight <sub>i</sub>	Composite <sub>i</sub>
1.	The ordinary shares of Sarepta Therapeutics Inc (the " <b>Sarepta Therapeutics Shares</b> ")	Not Applicable	Not Applicable
2.	The ordinary shares of BioMarin Pharmaceutical Inc (the " <b>BioMarin Pharmaceutical Shares</b> ")	Not Applicable	Not Applicable
3.	The ordinary shares of Neurocrine Biosciences Inc (the " <b>Neurocrine Biosciences Shares</b> ")	Not Applicable	Not Applicable
4.	The ordinary shares of Vertex Pharmaceuticals Inc (the " <b>Vertex Pharmaceuticals Shares</b> ")	Not Applicable	Not Applicable

53. Equity-linked Securities: Applicable
- Single Share, Share Basket or Multi-Asset Basket: Share Basket

**In respect of the Sarepta Therapeutics Inc Shares:**

- (i) Share Issuer: Sarepta Therapeutics Inc
- (ii) Share: The **Sarepta Therapeutics** Shares
- (iii) ISIN: US8036071004
- (iv) Bloomberg Code: SRPT UW <Equity>
- (v) Information Source: www.nasdaq.com
- (vi) Exchange: NASDAQ
- (vii) Related Exchange: All Exchanges
- (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1



(ix)	Adjustment basis for Share Basket and Reference Dates:	In respect of the Initial Setting Date, each Coupon Observation Date, the Final Fixing Date, the Knock-in Observation Date and each Trigger Barrier Observation Date: Share Basket and Reference Dates - Individual/Individual
(x)	Adjustment basis for Share Basket and Averaging Reference Dates:	Not Applicable
(xi)	Trade Date:	26 February 2021
(xii)	Jurisdictional Event:	Not Applicable
(xiii)	Jurisdictional Event Jurisdiction(s):	Not Applicable
(xiv)	Share Substitution:	Applicable
(xv)	Additional Disruption Events:	
	(a) Change in Law:	Change in Law Option 1 Applicable
	(b) Foreign Ownership Event:	Not Applicable
	(c) FX Disruption:	Not Applicable
	(d) Insolvency Filing:	Applicable
	(e) Hedging Disruption:	Applicable
	(f) Increased Cost of Hedging:	Not Applicable
	(g) Loss of Stock Borrow:	Not Applicable
	(h) Increased Cost of Stock Borrow:	Not Applicable

**In respect of the BioMarin Pharmaceutical Shares:**

(i)	Share Issuer:	BioMarin Pharmaceutical Inc
(ii)	Share:	The BioMarin Pharmaceutical Shares
(iii)	ISIN:	US09061G1013
(iv)	Bloomberg Code:	BMRN UW <Equity>
(v)	Information Source:	www.nasdaq.com
(vi)	Exchange:	NASDAQ
(vii)	Related Exchange:	All Exchanges
(viii)	Maximum Days of Disruption:	Eight Scheduled Trading Days as specified in Asset Term 1
(ix)	Adjustment basis for Share Basket and Reference Dates:	In respect of the Initial Setting Date, each Coupon Observation Date, the Final Fixing Date, the Knock-in Observation Date and each Trigger Barrier

Observation Date: Share Basket and Reference Dates - Individual/Individual

- (x) Adjustment basis for Share Basket and Averaging Reference Dates: Not Applicable
- (xi) Trade Date: 26 February 2021
- (xii) Jurisdictional Event: Not Applicable
- (xiii) Jurisdictional Event Jurisdiction(s): Not Applicable
- (xiv) Share Substitution: Applicable
- (xv) Additional Disruption Events:
  - (a) Change in Law: Change in Law Option 1 Applicable
  - (b) Foreign Ownership Event: Not Applicable
  - (c) FX Disruption: Not Applicable
  - (d) Insolvency Filing: Applicable
  - (e) Hedging Disruption: Applicable
  - (f) Increased Cost of Hedging: Not Applicable
  - (g) Loss of Stock Borrow: Not Applicable
  - (h) Increased Cost of Stock Borrow: Not Applicable

**In respect of the Neurocrine Biosciences Shares**

- (i) Share Issuer: Neurocrine Biosciences Inc
- (ii) Share: The Neurocrine Biosciences Shares
- (iii) ISIN: US64125C1099
- (iv) Bloomberg Code: NBIX UW <Equity>
- (v) Information Source: www.nasdaq.com
- (vi) Exchange: NASDAQ
- (vii) Related Exchange: All Exchanges
- (viii) Maximum Days of Disruption: Eight Scheduled Trading Days as specified in Asset Term 1
- (ix) Adjustment basis for Share Basket and Reference Dates: In respect of the Initial Setting Date, each Coupon Observation Date, the Final Fixing Date, the Knock-in Observation Date and each Trigger Barrier Observation Date: Share Basket and Reference Dates - Individual/Individual

- |        |  |                                   |
|--------|--|-----------------------------------|
| (x)    | Adjustment basis for Share Basket and Averaging Reference Dates: | Not Applicable                    |
| (xi)   | Trade Date:  | 26 February 2021                  |
| (xii)  | Jurisdictional Event:  | Not Applicable                    |
| (xiii) | Jurisdictional Event Jurisdiction(s):                            | Not Applicable                    |
| (xiv)  | Share Substitution:  | Applicable                        |
| (xv)   | Additional Disruption Events:                                    |                                   |
|        | (a) Change in Law:   | Change in Law Option 1 Applicable |
|        | (b) Foreign Ownership Event:                                     | Not Applicable                    |
|        | (c) FX Disruption:   | Not Applicable                    |
|        | (d) Insolvency Filing:   | Applicable                        |
|        | (e) Hedging Disruption:  | Applicable                        |
|        | (f) Increased Cost of Hedging:                                   | Not Applicable                    |
|        | (g) Loss of Stock Borrow:  | Not Applicable                    |
|        | (h) Increased Cost of Stock Borrow:                              | Not Applicable                    |

**In respect of the Vertex Pharmaceuticals Shares:**

- |        |  |  |
|--------|--|--|
| (i)    | Share Issuer:  | Vertex Pharmaceuticals Inc   |
| (ii)   | Share:   | The Vertex Pharmaceuticals Shares  |
| (iii)  | ISIN:  | US92532F1003   |
| (iv)   | Bloomberg Code:  | VRTX UW <Equity>   |
| (v)    | Information Source:                                    | www.nasdaq.com   |
| (vi)   | Exchange:  | NASDAQ   |
| (vii)  | Related Exchange:                                      | All Exchanges  |
| (viii) | Maximum Days of Disruption:                            | Eight Scheduled Trading Days as specified in Asset Term 1  |
| (ix)   | Adjustment basis for Share Basket and Reference Dates: | In respect of the Initial Setting Date, each Coupon Observation Date, the Final Fixing Date, the Knock-in Observation Date and each Trigger Barrier Observation Date: Share Basket and Reference Dates - Individual/Individual |

(x)	Adjustment basis for Share Basket and Averaging Reference Dates:	Not Applicable
(xi)	Trade Date:	26 February 2021
(xii)	Jurisdictional Event:	Not Applicable
(xiii)	Jurisdictional Event Jurisdiction(s):	Not Applicable
(xiv)	Share Substitution:	Applicable
(xv)	Additional Disruption Events:	
	(a) Change in Law:	Change in Law Option 1 Applicable
	(b) Foreign Ownership Event:	Not Applicable
	(c) FX Disruption:	Not Applicable
	(d) Insolvency Filing:	Applicable
	(e) Hedging Disruption:	Applicable
	(f) Increased Cost of Hedging:	Not Applicable
	(g) Loss of Stock Borrow:	Not Applicable
	(h) Increased Cost of Stock Borrow:	Not Applicable
54.	Index-linked Securities:	Not Applicable
55.	Commodity-linked Securities:	Not Applicable
56.	Commodity Index-linked Securities:	Not Applicable
57.	ETF-linked Securities:	Not Applicable
58.	ETC-linked Securities:	Not Applicable
59.	FX-linked Securities:	Not Applicable
60.	FX Index-linked Securities:	Not Applicable
61.	Inflation Index-linked Securities:	Not Applicable
62.	Interest Rate Index-linked Securities:	Not Applicable
63.	Cash Index-linked Securities:	Not Applicable
64.	Multi-Asset Basket-linked Securities:	Not Applicable
65.	Valuation Time:	As determined in accordance with Equity-linked Securities Asset Term 1

## **GENERAL PROVISIONS**

66.	(i) Form of Securities:	Bearer Securities
-----	-------------------------	-------------------

(ii)	Global Security:	Applicable
(iii)	NGN Form:	Not Applicable
(iv)	Intended to be held in a manner which would allow Eurosystem eligibility:	No. Whilst the designation is specified as "no" at the date of these Final Terms, should the Eurosystem eligibility criteria be amended in the future such that the Securities are capable of meeting them the Securities may then be deposited with one of the ICSDs as common safekeeper. Note that this does not necessarily mean that the Securities will then be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem at any time during their life. Such recognition will depend upon the European Central Bank being satisfied that Eurosystem eligibility criteria have been met
(v)	The Issuer intends to permit indirect interests in the Securities to be held through CREST Depository Interests to be issued by the CREST Depository:	Not Applicable
67.	Financial Centre(s):	Not Applicable
68.	Business Centre(s):	Not Applicable
69.	Listing and Admission to Trading:	Application will be made for the Securities to be listed on the Official List of the Luxembourg Stock Exchange and to be admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from or around the Issue Date provided, however, no assurance can be given that such application for listing and admission to trading will be granted (or, if granted, will be granted by the Issue Date or any specific date thereafter)
70.	Security Codes and Ticker Symbols:	
	ISIN:	XS2296366698
	Common Code:	229636669
	Swiss Security Number:	59953872
	Telekurs Ticker:	Not Applicable
	WKN Number:	Not Applicable
71.	Clearing and Trading:	
	Clearing System(s) and any relevant identification number(s):	Euroclear Bank S.A./N.V. and Clearstream Banking, <i>société anonyme</i>
72.	Delivery:	Delivery against payment
73.	Agents:	
	Calculation Agent:	Credit Suisse International One Cabot Square

London E14 4QJ

- Fiscal Agent: The Bank of New York Mellon, acting through its London Branch  
One Canada Square  
London E14 5AL
- Paying Agent(s): The Bank of New York Mellon, acting through its London Branch  
One Canada Square  
London E14 5AL
- Additional Agents: Not Applicable
74. Dealer(s): Credit Suisse International
75. Specified newspaper for the purposes of notices to Securityholders: Not Applicable
76. 871(m) Securities: The Issuer has determined that the Securities (without regard to any other transactions) should not be treated as transactions that are subject to U.S. withholding tax under section 871(m)
77. Prohibition of Sales to EEA and UK Retail Investors: Applicable – please see the cover page of these Final Terms
78. Additional U.S. Tax Selling Restrictions: Applicable – see "Additional U.S. Tax Selling Restrictions" under "UNITED STATES", as set out in the section headed "Selling Restrictions"
79. Additional Provisions: Not Applicable

## PART B – OTHER INFORMATION

**TERMS AND CONDITIONS OF THE OFFER** Not Applicable

### INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

So far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the issue, save for any fees payable to the distributor(s).

The Securities will be sold by the Dealer to the distributor(s) at a discount of up to 6 per cent. of the Issue Price. Such discount represents the fee retained by the distributor(s) out of the Issue Price paid by investors, equivalent to approximately 2 per cent. of the Specified Denomination per Security per annum. The Issue Price and the terms of the Securities take into account such fee and may be more than the market value of the Securities on the Issue Date.

### PERFORMANCE OF SHARE/INDEX/COMMODITY/COMMODITY INDEX/ETF SHARE/ETC/FX RATE/FX INDEX/INFLATION INDEX/INTEREST RATE INDEX/CASH INDEX AND OTHER INFORMATION CONCERNING THE UNDERLYING ASSET(S)

Information in relation to each of the Underlying Assets, including information about the past and future performance and volatility of such Underlying Assets, can be found free of charge at, in respect of:

- (a) the Sarepta Therapeutics Inc Shares, [www.nasdaq.com](http://www.nasdaq.com);
- (b) the BioMarin Pharmaceutical Inc Shares, [www.nasdaq.com](http://www.nasdaq.com);
- (c) the Neurocrine Biosciences Inc Shares, [www.nasdaq.com](http://www.nasdaq.com); and
- (d) the Vertex Pharmaceuticals Inc Shares, [www.nasdaq.com](http://www.nasdaq.com),

but the information appearing on such websites does not form part of these Final Terms.

The Securities relate to a basket of Underlying Assets. The Securities have a "worst of" feature and therefore no weightings apply.


### POST-ISSUANCE INFORMATION

The Issuer will not provide any post-issuance information with respect to the Underlying Assets, unless required to do so by applicable law or regulation.

### REASONS FOR THE ISSUE, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

- |                                 |   |
|---------------------------------|---|
| (i) Reasons for the issue:      | See "Use of Proceeds" section in the Securities Note. |
| (ii) Estimated net proceeds:    | USD 1,200,000   |
| (iii) Estimated total expenses: | Not Applicable.                                       |

Signed on behalf of the Issuer:

By:  **Julien Bieren**  
Managing Director  
Duly authorised

By:  **Dominic Savage**  
Authorised Signatory  
Duly authorised